# SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

> **NCT05398614** · PHASE1 · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- T-ALL
- Lymphoma, T-Cell

## Interventions

- **BIOLOGICAL:** SENL101

## Key facts

- **NCT ID:** NCT05398614
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398614, "SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05398614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*